Philogen´s research and development activities for the identification of novel targeting agents rely on proprietary technology platforms such as  antibody libraries and DNA-encoded chemical libraries. Both platforms have proven to deliver best-in-class ligands with high affinity and specificity and with powerful in vivo targeting properties.



By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy